3 May 2002
Source: http://www.access.gpo.gov/su_docs/aces/fr-cont.html

-------------------------------------------------------------------------

[Federal Register: May 3, 2002 (Volume 67, Number 86)]
[Notices]               
[Page 22414]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr03my02-38]                         

-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Department of the Army

 
Availability for Non-Exclusive, Exclusive, or Partially Exclusive 
Licensing of U.S. Patent Application Concerning Method for Purifying 
Cholera Toxin

AGENCY: Department of the Army, DoD.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: In accordance with 37 CFR 404.6 and 404.7, announcement is 
made of the availability for licensing of U.S. Patent No. 6,008,329 
entitled ``Method for Purifying Cholera Toxin'' filed March 6, 1998. 
Foreign rights are also available (PCT/US99/05005). The United States 
Government as represented by the Secretary of the Army has rights in 
this invention.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, 
ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, 
Frederick, MD 21702-5012.

FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth 
Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul 
Mele, Office of Research & Technology Assessment, (301) 619-6664, both 
at telefax (301) 619-5034.

SUPPLEMENTARY INFORMATION: This invention relates to a method of 
purifying cholera toxin using a matrix with at least one ion chosen 
from among matrix with Ni+2, Co+2, Cd2 or Zn+2 immobilized 
thereon. It is possible thereby to selectively elute the B subunit for 
cholera toxin from the matrix.

Luz D. Ortiz,
Army Federal Register Liaison Officer.
[FR Doc. 02-11071 Filed 5-2-02; 8:45 am]
BILLING CODE 3710-08-M

-----------------------------------------------------------------------

[Federal Register: May 3, 2002 (Volume 67, Number 86)]
[Notices]               
[Page 22414]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr03my02-39]                         

-----------------------------------------------------------------------

[Federal Register: May 3, 2002 (Volume 67, Number 86)]
[Notices]               
[Page 22412-22413]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr03my02-33]                         

-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Department of the Army

 
Availability for Non-Exclusive, Exclusive, or Partially Exclusive 
Licensing of U.S. Patent Application Concerning Asporogenic B. 
ANTHRACIS Expression System

AGENCY: Department of the Army, DOD.

ACTION: Notice.

-----------------------------------------------------------------------

[[Page 22413]]

SUMMARY: In accordance with 37 CFR 404.6 and 404.7, announcement is 
made of the availability for licensing of U.S. Patent No. 6,316,006 
entitled ``Asporogenic B. ANTHRACIS Expression System'' issued November 
13, 2001. The United States Government as represented by the Secretary 
of the Army has rights in this invention.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, 
ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, 
Frederick, MD 21705-5012.

FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth 
Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul 
Mele, Office of Research & Technology Assessment, (301) 619-6664, both 
at telefax (301) 619-5034.

SUPPLEMENTARY INFORMATION: This invention relates to a bacterial 
expression system for production of protective antigen (PA) against 
bacillus anthrasis. Recombinant asporogenic B. anthracits that are 
derived from Sterne-1(pPA102) and show inability to bind the 
dye when grown on Congo Red Agar can be screened and asporogenic 
strains isolated using methods of the invention. Organisms of the 
invention lacking spore-forming function may be killed by heat shock at 
temperatures as low as 
60  deg.C. for 60 minutes. Hence, contamination of the environment with 
viable spore-forming organisms is easily avoided and decontamination is 
easily accomplished.

Luz D. Ortiz,
Army Federal Register Liaison Officer.
[FR Doc. 02-11067 Filed 5-2-02; 8:45 am]
BILLING CODE 3710-08-M

-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Department of the Army

 
Availability for Non-Exclusive, Exclusive, or Partially Exclusive 
Licensing of U.S. Patent Application Concerning a Method of Making a 
Vaccine for Anthrax

AGENCY: Department of the Army, DoD.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: In accordance with 37 CFR 404.6 and 404.7, announcement is 
made of the availability for licensing of U.S. Patent Application 
Serial No. 09/520,215 entitled ``Method of Making a Vaccine for 
Anthrax,'' filed March 7, 2000. The United States Government, as 
represented by the Secretary of the Army has rights in this invention.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, 
ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, 
Frederick, MD 21702-5012.

FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth 
Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul 
Mele, Office of Research & Technology Assessment, (301) 619-6664, both 
at telefax (301) 619-5034.

SUPPLEMENTARY INFORMATION: A method of making a vaccine from a 
protective antigen. The protective antigen is useful against Bacillus 
anthracis. The protective antigen is produced by an asporogenic 
organism, which overproduces the desired antigen. The asporogenic 
organism is a recombinant asporogenic B. anthracis. The recombinant 
asporogenic B. anthracis was derived from a  Sterne-1(pPA102) 
strain of bacteria and binds to dye when grown on Congo Red Agar.

Luz D. Ortiz,
Army Federal Register Liaison Officer.
[FR Doc. 02-11072 Filed 5-2-02; 8:45 am]
BILLING CODE 3710-08-M

-----------------------------------------------------------------------

[Federal Register: May 3, 2002 (Volume 67, Number 86)]
[Notices]               
[Page 22413]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr03my02-34]                         

-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Department of the Army

 
Availability for Non-Exclusive, Exclusive, or Partially Exclusive 
Licensing of U.S. Patent Application Concerning Burkholderia Toxins

AGENCY: Department of the Army, DoD.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: In accordance with 37 CFR 404.6 and 404.7, announcement is 
made of the availability for licensing of U.S. Patent Application No. 
09/770,714 entitled ``Burkholderia Toxins'' filed January 26, 2001. The 
United States Government as represented by the Secretary of the Army 
has rights in this invention.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, 
ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, 
Frederick, MD 21702-5012.

FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth 
Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul 
Mele, Office of Research & Technology Assessment, (301) 619-6664, both 
at telefax (301) 619-5034.

SUPPLEMENTARY INFORMATION: A novel composition comprising toxins 
produced from Burkholderia species is described and is effective in 
inhibiting nematode growth.

 Luz D. Ortiz,
Army Federal Register Liaison Officer.
[FR Doc. 02-11066 Filed 5-2-02; 8:45 am]
BILLING CODE 3710-08-M

-----------------------------------------------------------------------
